Literature DB >> 30042175

R1 Regulates Prostate Tumor Growth and Progression By Transcriptional Suppression of the E3 Ligase HUWE1 to Stabilize c-Myc.

Tzu-Ping Lin1,2,3,4, Jingjing Li5, Qinlong Li6,7, Xiangyan Li6, Chunyan Liu6, Ni Zeng1, Jen-Ming Huang6, Gina Chia-Yi Chu5, Chi-Hung Lin8, Haiyen E Zhau6, Leland W K Chung6, Boyang Jason Wu9, Jean C Shih10,2,11.   

Abstract

Prostate cancer is a prevalent public health problem, especially because noncutaneous advanced malignant forms significantly affect the lifespan and quality of life of men worldwide. New therapeutic targets and approaches are urgently needed. The current study reports elevated expression of R1 (CDCA7L/RAM2/JPO2), a c-Myc-interacting protein and transcription factor, in human prostate cancer tissue specimens. In a clinical cohort, high R1 expression is associated with disease recurrence and decreased patient survival. Overexpression and knockdown of R1 in human prostate cancer cells indicate that R1 induces cell proliferation and colony formation. Moreover, silencing R1 dramatically reduces the growth of prostate tumor xenografts in mice. Mechanistically, R1 increases c-Myc protein stability by inhibiting ubiquitination and proteolysis through transcriptional suppression of HUWE1, a c-Myc-targeting E3 ligase, via direct interaction with a binding element in the promoter. Moreover, transcriptional repression is supported by a negative coexpression correlation between R1 and HUWE1 in a prostate cancer clinical dataset. Collectively, these findings, for the first time, characterize the contribution of R1 to prostate cancer pathogenesis. IMPLICATIONS: These findings provide evidence that R1 is a novel regulator of prostate tumor growth by stabilizing c-Myc protein, meriting further investigation of its therapeutic and prognostic potential. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30042175     DOI: 10.1158/1541-7786.MCR-16-0346

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  4 in total

1.  Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma.

Authors:  Elena Bonazzoli; Stefania Bellone; Luca Zammataro; Barbara Gnutti; Adele Guglielmi; Silvia Pelligra; Nupur Nagarkatti; Paola Manara; Joan Tymon-Rosario; Burak Zeybek; Gary Altwerger; Gulden Menderes; Chanhee Han; Elena Ratner; Dan-Arin Silasi; Gloria S Huang; Vaagn Andikyan; Masoud Azodi; Peter E Schwartz; Alessandro D Santin
Journal:  Gynecol Oncol       Date:  2020-06-26       Impact factor: 5.482

2.  Notch-1 inhibition reduces proliferation and promotes osteogenic differentiation of bone marrow mesenchymal stem cells.

Authors:  Ying He; Lijin Zou
Journal:  Exp Ther Med       Date:  2019-07-10       Impact factor: 2.447

3.  The LEDGF/p75 Integrase Binding Domain Interactome Contributes to the Survival, Clonogenicity, and Tumorsphere Formation of Docetaxel-Resistant Prostate Cancer Cells.

Authors:  Greisha L Ortiz-Hernandez; Evelyn S Sanchez-Hernandez; Pedro T Ochoa; Catherine C Elix; Hossam R Alkashgari; James R W McMullen; Ubaldo Soto; Shannalee R Martinez; Carlos J Diaz Osterman; Michael Mahler; Sourav Roy; Carlos A Casiano
Journal:  Cells       Date:  2021-10-12       Impact factor: 7.666

4.  Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.

Authors:  Lei Zhu; Zhen Chen; Hongjing Zang; Songqing Fan; Jiajia Gu; Guojing Zhang; Kevin D-Y Sun; Qiming Wang; Yong He; Taofeek K Owonikoko; Suresh S Ramalingam; Shi-Yong Sun
Journal:  Cancer Res       Date:  2021-07-21       Impact factor: 12.701

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.